Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15%-Reference-Cited by-同舟云学术

Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15%

Published:2004-12 Issue:6 Volume:64 Page:1160-1164
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Khan Masood A.,Sokoll Lori J.,Chan Daniel W.,Mangold Leslie A.,Mohr Phaedre,Mikolajczyk Stephen D.,Linton Harry J.,Evans Cindy L.,Rittenhouse Harry G.,Partin Alan W.

Publisher

Elsevier BV

Subject

Urology

Reference19 articles.

1. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer;Woodrum;J Urol,1998

2. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer;Levine;J Urol,1998

3. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin;Lilja;Clin Chem,1991

4. A complex between prostate specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer;Stenman;Cancer Res,1991

5. Use of the percentage of free PSA to enhance differentiation of prostate cancer from benign prostatic disease;Catalona;JAMA,1998

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Label-free Electrochemical Immunosensor Based on Gold Nanoparticles-poly(ferriporphyrin-co-acrylamide)-reduced Graphene Oxide and the Application in Prostate Specific Antigen Detection;Electrochemistry;2024-02-20

2. Multiplexed quantitative proteomics in prostate cancer biomarker development;Advances in Cancer Research;2024

3. Current and emerging tissue‐based molecular biomarkers for prostate cancer management: A narrative review;UroPrecision;2023-09

4. The Clinical Usefulness of Prostate Cancer Biomarkers: Current and Future Directions;Biomedical Engineering;2022-09-28

5. Biomarkers for Diagnosis and Prognosis of Prostate Cancer;Prostatectomy;2019-05-29